


## Glaucocalyxin A

## Chemical Properties

|                   |  |
|-------------------|--|
| CAS No. :         | 79498-31-0   |
| Formula:          | C <sub>20</sub> H <sub>28</sub> O <sub>4</sub>   |
| Molecular Weight: | 332.43   |
| Storage:          | Keep away from direct sunlight<br>Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br><i>Actual storage temperature shall be subject to the COA.</i> |



## Biological Description

|               |   |
|---------------|---|
| Description   | 1. Glaucocalyxin A (Leukamenin F)-SBE- $\beta$ -CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. 3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. 4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cy2, the signaling events in collagen receptor GPVI pathway. 5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand. |
| Targets(IC50) | Apoptosis,Akt,Caspase,PI3K  |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | Chloroform, Dichloromethane, Ethyl Acetate, Acetone, etc.: Soluble,<br>DMSO: 6.88 mg/mL (20.7 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)  |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.01 mM),Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 3.0082 mL | 15.0408 mL | 30.0815 mL |
| 5 mM  | 0.6016 mL | 3.0082 mL  | 6.0163 mL  |
| 10 mM | 0.3008 mL | 1.5041 mL  | 3.0082 mL  |
| 50 mM | 0.0602 mL | 0.3008 mL  | 0.6016 mL  |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Xiao X , Cao W , Jiang X , et al. Glaucoalyxin A, a negative Akt regulator, specifically induces apoptosis in human brain glioblastoma U87MG cells[J].2013, 45(11):946-52.

Hou X, Xu G, Wang Z, et al. Glaucoalyxin A alleviates LPS-mediated septic shock and inflammation via inhibiting NLRP3 inflammasome activation. International Immunopharmacology. 2020, 81: 106271

Hou X, Xu G, Wang Z, et al. Glaucoalyxin A alleviates LPS-mediated septic shock and inflammation via inhibiting NLRP3 inflammasome activation[J]. International Immunopharmacology. 2020, 81: 106271.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481